Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 4 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva 2020-10-20
ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group 2020-10-20
Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners 2020-10-19
Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF 2020-10-19
Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures 2020-10-19
Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital 2020-10-19
Topas Therapeutics–Evotec: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Evotec 2020-10-19
Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv 2020-10-19
Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors 2020-10-19
Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III 2020-10-19
Azitra–Bayer: investment, 202010 financing round Series B totalling $17m incl $8m from lead investor Leaps by Bayer 2020-10-15
Azitra–SEVERAL: investment, 202010 financing round Series B $17m led by Leaps by Bayer 2020-10-15
VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors 2020-10-15
RayzeBio–SEVERAL: investment, 202010 financing round Series A $45m co-led by venBio Partners + Versant Ventures 2020-10-14
Chord Therapeutics–Omega Funds: investment, 202010 financing Series A $16m from sole investor Omega Funds 2020-10-13
Chord Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum 2020-10-13
Iksuda Therapeutics–Univ Göttingen: antibody-drug conjugates, 202010– license excl ww to new class of prodrug payloads for ADCs using PermaLink 2020-10-13
Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund 2020-10-13
Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds 2020-10-13
Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital 2020-10-12
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners 2020-10-12
Sensei Biotherapeutics–Angermayer Group: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Apeiron Investment Group 2020-10-07
Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures 2020-10-07
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis 2020-10-06
Heartbeat Medical–btov Partners: investment, 202010 financing round Series A totalling €5m incl new + co-lead investor btov Partners 2020-10-05
Heartbeat Medical–High-Tech Gründerfonds: investment, 202010 financing round Series A totalling €5m incl existing + co-investor HTGF 2020-10-05
Heartbeat Medical–Holtzbrinck: investment, 202010 financing round Series A totalling €5m incl existing + co-lead investor HV Holtzbrinck Ventures 2020-10-05
Heartbeat Medical–SEVERAL: investment, 202010 financing round Series A €5m co-led by btov Partners + HV Holtzbrinck Ventures + incl HTGF 2020-10-05
BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED 2020-10-02
Sophia Genetics–ACE & Company: investment, 202010 financing round Series F totalling $110m incl new + co-investor ACE & Co 2020-10-01
Sophia Genetics–Alychlo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Alychlo 2020-10-01
Sophia Genetics–aMoon: investment, 202010 financing round Series F totalling $110m incl co-lead investor aMoon 2020-10-01
Sophia Genetics–Credit Suisse: investment, 202010 financing round Series F totalling $110m incl co-investor Credit Suisse 2020-10-01
Sophia Genetics–Endeavour Vision: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Endeavour Vision 2020-10-01
Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth 2020-10-01
Sophia Genetics–Famille C Invest: investment, 202010 financing round Series F totalling $110m incl new + co-investor Famille C Invest 2020-10-01
Sophia Genetics–Generation Investment Management: investment, 202010 financing round Series F totalling $110m incl existing + co-investor GIM 2020-10-01
Sophia Genetics–Hitachi: investment, 202010 financing round Series F totalling $110m incl co-lead investor Hitachi Ventures 2020-10-01
Sophia Genetics–Pictet: investment, 202010 financing round Series F totalling $110m incl co-investor Pictet Group 2020-10-01
Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures 2020-10-01
Sophia Genetics–Swisscom: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Swisscom Ventures 2020-10-01
Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR 2020-10-01
Integrated Proteomics Applications–Bruker: investment, 202009 acquisition €na of assets by Bruker 2020-09-30
Vedere Bio–Novartis: investment, 202009 acquisition $150m upfront + $130m milestones with some assets spun out before into Vedere BIo II 2020-09-30
Dewpoint Therapeutics–ARCH Venture: investment, 202009 financing round Series B totalling $77m incl lead investor ARCH Venture Partners 2020-09-29
Dewpoint Therapeutics–Bayer: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Leaps by Bayer 2020-09-29
Dewpoint Therapeutics–Bellco Capital: investment, 202009 financing round Series B totalling $77m incl new + co-investor Bellco Capital 2020-09-29
Dewpoint Therapeutics–EcoR1 Capital: investment, 202009 financing round Series B totalling $77m incl existing + co-investor EcoR1 Capital 2020-09-29
Dewpoint Therapeutics–Innovation Endeavors: investment, 202009 financing round Series B totalling $77m incl existing + co-investor IE 2020-09-29
Dewpoint Therapeutics–Maverick Ventures: investment, 202009 financing round Series B totalling $77m incl new + co-investor Maverick Ventures 2020-09-29
Dewpoint Therapeutics–Polaris Partners: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Polaris Partners 2020-09-29
Dewpoint Therapeutics–Samsara BioCapital: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Samsara BioCapital 2020-09-29
Dewpoint Therapeutics–SEVERAL: investment, 202009 financing round Series B $77m led by ARCH Venture Partners 2020-09-29
Kurma–SEVERAL: investment, 202009 first closing €50m of Kurma Diagnostics 2 Fund (KDx2) 2020-09-29
Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL 2020-09-28
XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside 2020-09-28
XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG 2020-09-28
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures 2020-09-25
Mosa Meat–Bell Food: investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor Bell Food Group 2020-09-25
Mosa Meat–Blue Horizon Ventures: investment, 202009 financing round Series B 1st closing totalling $55m incl new + lead investor Blue Horizon Ventures 2020-09-25
Mosa Meat–Merck (DE): investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor M Ventures 2020-09-25
Mosa Meat–SEVERAL: investment, 202009 financing round Series B 1st closing $55m led by Blue Horizon Ventures 2020-09-25
Monte Rosa Therapeutics–1AB Media: public relations, 202009 service existent by 1AB Media 2020-09-24
Monte Rosa Therapeutics–Aisling Capital: investment, 202009 financing round Series B totalling $96m incl new + lead investor Aisling Capital 2020-09-24
Monte Rosa Therapeutics–Alphabet: investment, 202009 financing round Series B totalling $96m incl new + co-investor GV 2020-09-24
Monte Rosa Therapeutics–Amzak Health: investment, 202009 financing round Series B totalling $96m incl new + co-investor Amzak Health 2020-09-24
Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor CAM 2020-09-24
Monte Rosa Therapeutics–Casdin Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Casdin Capital 2020-09-24
Monte Rosa Therapeutics–Cormorant Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor Cormorant 2020-09-24
Monte Rosa Therapeutics–HBM: investment, 202009 financing round Series B totalling $96m incl new + co-investor HBM Healthcare Investments 2020-09-24
Monte Rosa Therapeutics–New Enterprise Associates: investment, 202009 financing round Series B totalling $96m incl existing + co-investor NEA 2020-09-24
Monte Rosa Therapeutics–SEVERAL: investment, 202009 financing round Series B $96m led by AIsling Capital 2020-09-24
Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Sixty Degree Capital 2020-09-24
Monte Rosa Therapeutics–Versant Ventures: investment, 202009 financing round Series B totalling $96m incl existing + co-investor Versant Ventures 2020-09-24
AM-Pharma–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP 2020-09-23
Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund 2020-09-23
Libra Therapeutics–Boehringer: investment, 202009 financing round Series A totalling $29m incl co-lead investor BIVF 2020-09-23
Libra Therapeutics–SEVERAL: investment, 202009 financing round Series A $29m co-led by BIVF + Epidarex Capital + Santé 2020-09-23
ERS Genomics–Zyme Communications: public relations, 202009 service existent by Zyme 2020-09-22
Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED 2020-09-22
Salvia BioElectronics–SEVERAL: investment, 202009 financing round Series A €21m co-led by Panakès Partners + Inkef Capital + SHS 2020-09-22
Salvia BioElectronics–SHS: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor SHS 2020-09-22
Immune Regulation–Metellus: investment, 202009– financing round Series B totalling £40.6m incl co-investor Metellus AG 2020-09-21
Immune Regulation–SEVERAL: investment, 202009– financing round Series B £40.6m in two tranches + incl £6m advance subscription funds 2020-09-21
Inflazome–Byrne Wallace: legal services, 202009 supply service Byrne Wallace is legal advisor with regard to acquisition of Inflazome by Roche 2020-09-21
Inflazome–Goodwin Procter: legal services, 202009 supply service Goodwin Procter is legal advisor with regard to acquisition of Inflazome by Roche 2020-09-21
Inflazome–Lazard: financial services, 202009 supply service Lazard financial advisor with regard to acquisition of Inflazome by Roche 2020-09-21
Inflazome–Roche: investment, 202009 acquisition of Inflazome by Roche for €380m upfront + milestones 2020-09-21
Infarm–SEVERAL: investment, 202009 financing round Series C first closing $170m led by LGT Lightstone 2020-09-17
Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures 2020-09-17
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures 2020-09-17
Novartis–BioNTech: investment, 202009– acquisition of Novartis GMP Biologics Manufacturing Site in Marburg by BioNTech 2020-09-17
Dinaqor–KWM Communications: public relations, 202009 service existent by KWM Communications 2020-09-16
Maetrics–Regulatory and Quality Solutions: investment, 202009 acquisition of Maetrics by R&Q 2020-09-16
Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact 2020-09-16
ImCheck Therapeutics–Bellevue: investment, 202009 financing round Series B extension €6m from BB Pureos Bioventures bringing total Series B to €54m 2020-09-15
Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 2020-09-14
Boehringer–Click Therapeutics: digital therapeutics, 202009– collab ufpront+milestones >$500m + royalties ww dev+marketing CT-155 for schizophrenia 2020-09-11
Canopy Biosciences–Bruker: investment, 202009 acquisition €na of Canopy Biosciences LLC by Bruker Corp 2020-09-11
Sumitomo–Gain Therapeutics: small-molecule drugs, 202009– collab strategic r+d targeting allosteric sites in lysosomal enzymes using SEE-Tx 2020-09-10
next pagenext page 1 2 3 4 ... 29 30 31  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top